title: Payers' costly battle against cancer.
abstract: In a classic managed care struggle between cost containment and physician autonomy, health plans' efforts to rein in the expense of biotech cancer drugs are meeting stiff resistance from oncologists. They staunchly defend their practice of buying such drugs and marking up their prices to cover service costs as a critical component of cancer care. Here's a look at the issues on both sides.
authors: Chuck
authors: C
authors: Appleby